Current Report Filing (8-k)
May 12 2016 - 3:26PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): May 12, 2016 (May 9, 2016)
Neuralstem, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On May 9, 2016, Neuralstem, Inc. (the “Company”)
issued a press release announcing its financial results for the three months ended March 31, 2016 and providing a business and
clinical programs update. The press release is attached hereto as Exhibit 99.01 and is incorporated herein by reference.
The information furnished under Items
2.02, including the accompanying Exhibit 99.01 shall not be deemed to be “filed” for the purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor
shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities
Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated
in such filing.
On May 12, 2016, the Company announced
that the first patient has been enrolled in the double-blind, placebo-controlled multi-center Phase 2 study of NSI-189 for the
treatment of major depressive disorder. A copy of the press release is attached to this report as Exhibit 99.02.
|
Item
9.01
|
Financial
Statement and Exhibits.
|
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.01
99.02
|
|
Press Release Dated May 9, 2016
Press Release Dated May 12, 2016
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
May 12, 2016
|
Neuralstem, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Richard Daly
|
|
|
|
By: Richard Daly
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
INDEX OF EXHIBITS
Exhibit
No.
|
|
Description
|
|
|
99.01
99.02
|
|
Press Release Dated May 9, 2016
Press Release Dated May 12, 2016
|
|
|
|
|
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Neuralstem Inc (NASDAQ): 0 recent articles
More Neuralstem, Inc. News Articles